CureVac

CureVac N.V., based in Tübingen, Germany, was an early mRNA technology company. In oncology it advanced CVGBM, an off-the-shelf mRNA cancer vaccine encoding shared tumour-associated antigens for glioblastoma, and CVHNLC, a second oncology candidate, alongside partnered mRNA programmes and a broad mRNA manufacturing and intellectual property estate. The company's website now states that BioNTech has successfully closed its acquisition of CureVac and that CureVac is part of the BioNTech Group (Nasdaq: BNTX), redirecting visitors to biontech.com. Detailed programme status is now reported within BioNTech's pipeline. The acquisition consideration and closing date could not be confirmed from a fetched primary source (BioNTech's investor site blocked automated access), so the deal is recorded without an amount.